ClinicalTrials.gg
TerminatedNCT02051764Updated Sep 7, 2020Results posted

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

A Phase 2 interventional study of Flortaucipir F18 and Florbetapir F 18 in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-07.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2, Interventional, and Diagnostic

Why this study was terminated
Lower than expected enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
13th of 22
44 · median 70
Started
2014
with 3 others
Phase 2
6 of 22
none open now
Registered
3rd of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 13th largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 2, and was the 3rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a previous 18F-AV-1451 brain scan
  • Can tolerate up to two Positron Emission Tomography (PET) imaging sessions and a Magnetic Resonance Imaging (MRI) scan
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Current psychiatric disease
  • Are claustrophobic
  • Current clinically significant cardiovascular disease or abnormalities, or additional risk factors for Torsades de Pointes
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Females of who are not surgically sterile, not refraining from sexual activity or not using reliable methods of
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Follow-up Flortaucipir PET Scan

    Drug: Flortaucipir F18 · Drug: Florbetapir F 18 · Procedure: Brain PET Scan

Interventions

  • 370 megabecquerel (MBq) IV single-dose

    Also known as: 18F-AV-1451, LY3191748, [F-18]T807

  • 370 megabecquerel (MBq) IV single-dose

    Also known as: Amyvid, 18F-AV-45

  • ProcedureBrain PET Scan

    positron emission tomography (PET) scan of the brain

06

What researchers measure

Primary outcomes

  1. Change in Tau Deposition

    Rate of tau deposition change as measured by flortaucipir standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline scan and at least 6 months after baseline scan

07

Results

Posted Sep 7, 2020

Participant flow

Enrolled subjects who had previously undergone flortaucipir PET (positron emission tomography) scans in other Avid-sponsored (NCT04474405 and NCT01992380) and non-Avid protocols and brought back to the clinic a minimum of 6 months after the initial flortaucipir PET scan for cognitive testing and an additional flortaucipir scan.

Participant flow — Overall Study
MilestoneCognitively ImpairedHealthy Volunteers
Started1628
Completed1621
Not completed07
Withdrew: Study terminated by sponsor07

Outcome measures

PrimaryChange in Tau Deposition

Rate of tau deposition change as measured by flortaucipir standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline scan and at least 6 months after baseline scan
Reported as:
Mean · standardized uptake value ratio (SUVr)
Change in Tau Deposition
standardized uptake value ratio (SUVr)Cognitively ImpairedHealthy Volunteers
Overall0.0347 ± 0.047-0.0008 ± 0.013
Amyloid Negative0.0364 ± 0.082-0.0026 ± 0.013
Amyloid Positive0.0345 ± 0.045-0.0002 ± 0.013
Statistical analysis
  • Cognitively Impaired vs Healthy Volunteers · ANCOVA · p = 0.2837 (Not adjusted for multiple comparisons. No a priori threshold was selected.)Adjustments included baseline tau deposition, age, time (in years) between imaging, and included an interaction of time and enrolling diagnosis.
  • Cognitively Impaired vs Healthy Volunteers · ANCOVA · p = 0.9276 (Not adjusted for multiple comparisons. No a priori threshold was selected.)Adjustments included baseline tau deposition, age, time (in years) between imaging, and included an interaction of time and enrolling diagnosis.
  • Cognitively Impaired vs Healthy Volunteers · ANCOVA · p = 0.6324 (Not adjusted for multiple comparisons. No a priori threshold was selected.)Adjustments included baseline tau deposition, age, time (in years) between imaging, and included an interaction of time and enrolling diagnosis.

Adverse events

Collected over Administration of study drug until 48 hours post administration. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitively Impaired0/16 (0%)0/16 (0%)1/16 (6.3%)
Healthy Volunteers0/21 (0%)0/21 (0%)0/21 (0%)
Most frequent other events
Most frequent other events
EventCognitively ImpairedHealthy Volunteers
HeadacheNervous system disorders1/16—

Baseline characteristics

Excluded 7 subjects who did not receive a flortaucipir scan

Age, Continuous
Age, Continuous(years)Cognitively ImpairedHealthy VolunteersTotal
Mean67.6 ± 9.1575.3 ± 4.9871.9 ± 7.98
Sex: Female, Male
Sex: Female, Male(Participants)Cognitively ImpairedHealthy VolunteersTotal
Female279
Male141428
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cognitively ImpairedHealthy VolunteersTotal
Hispanic or Latino000
Not Hispanic or Latino162137
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cognitively ImpairedHealthy VolunteersTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White161935
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cognitively ImpairedHealthy VolunteersTotal
United States162137
Amyloid status
Amyloid status(Participants)Cognitively ImpairedHealthy VolunteersTotal
Positive141630
Negative257
08

Study locations

4 sites
  • Hoag Memorial Hospital
    Newport Beach, California 92663, United States
  • UC Irvine Medical Center
    Orange, California 92868, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Center for Clinical Imaging Research, Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Dec 2016, 31 months.

Results were first posted in Sep 2020, 3 years 9 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2014
First posted
Jan 31, 2014
StartActual
May 2014
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results delay requested
Feb 8, 2017
Results first posted
Sep 7, 2020
Last update
Sep 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02051764
Responsible party
Sponsor
First posted
Jan 31, 2014
Start date
May 2014
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Sep 7, 2020
Last update
Sep 7, 2020

Study contacts

Chief Medical Officer
study chair · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion